COST-EFFECTIVENESS OF ABATACEPT FOR THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO METHOTREXATE IN CHILE

被引：0
|
作者：
Elgart, J. F. [1 ]
Gonzalez, L. [1 ]
Aiello, E. C. [2 ]
机构：
[1] UNLP CONICET La Plata, Ctr Colaborador OPS OMS, CENEXA Ctr Endocrinol Expt & Aplicada, La Plata, Buenos Aires, Argentina
[2] Bristol Myers Squibb, Buenos Aires, DF, Argentina
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A223 / A223
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Methotrexate and Sulfasalazine in Rheumatoid Arthritis: A Comparative Study
    Bhatt, K.
    Girish, K.
    Pundarikaksha, H. P.
    Tamboli, T.
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 : S54 - S54
  • [42] ABATACEPT OR INFLIXIMAB FOR PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE: A TRIAL-BASED AND REAL-LIFE COST-CONSEQUENCE ANALYSIS
    Benucci, M.
    Stam, W.
    Gilloteau, I
    Crocchiolo, D.
    Sennfaelt, K.
    Leclerc, A.
    Bengtsson, N.
    Maetzel, A.
    Lucioni, C.
    VALUE IN HEALTH, 2011, 14 (07) : A307 - A307
  • [43] Cost-Effectiveness Analysis of Abatacept Compared with Adalimumab on Background Methotrexate in Biologic-Naive Adult Patients with Rheumatoid Arthritis and Poor Prognosis
    Alemao, Evo
    Johal, Sukhvinder
    Al, Maiwenn J.
    Rutten-van Molken, Maureen
    VALUE IN HEALTH, 2018, 21 (02) : 193 - 202
  • [44] Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
    Muszbek, Noemi
    Proudfoot, Clare
    Fournier, Marie
    Chen, Chieh-I
    Kuznik, Andreas
    Kiss, Zsofia
    Gal, Peter
    Michaud, Kaleb
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (11): : 1268 - 1280
  • [45] COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE
    Gossec, L.
    Goupille, P.
    Saraux, A.
    Bregman, B.
    Boccard, E.
    Dupont, D.
    Beresniak, A.
    VALUE IN HEALTH, 2008, 11 (06) : A542 - A543
  • [46] Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study
    D'Agostino, Maria-Antonietta
    Wakefield, Richard J.
    Berner-Hammer, Hilde
    Vittecoq, Olivier
    Filippou, Georgios
    Balint, Peter
    Moeller, Ingrid
    Iagnocco, Annamaria
    Naredo, Esperanza
    Ostergaard, Mikkel
    Boers, Maarten
    Gaillez, Corine
    Van Holder, Karina
    Le Bars, Manuela
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (10) : 1763 - 1769
  • [47] THE COST-EFFECTIVENESS OF LIVER-BIOPSY IN RHEUMATOID-ARTHRITIS PATIENTS TREATED WITH METHOTREXATE
    BERGQUIST, SR
    FELSON, DT
    PRASHKER, MJ
    FREEDBERG, KA
    ARTHRITIS AND RHEUMATISM, 1995, 38 (03): : 326 - 333
  • [48] A cost-effectiveness analysis of biological agents for patients with moderate to severe rheumatoid arthritis following inadeqaute response to methotrexate
    Gandhi, P. K.
    Spooner, J. J.
    Viraparia, P.
    Kauf, T. L.
    VALUE IN HEALTH, 2008, 11 (03) : A258 - A259
  • [49] Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis
    Benucci, M.
    Stam, W. B.
    Gilloteau, I.
    Sennfaelt, K.
    Leclerc, A.
    Maetzel, A.
    Lucioni, C.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : 575 - 583
  • [50] Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life
    Benucci, Maurizio
    Saviola, Gianantonio
    Baiardi, Paola
    Manfredi, Mariangela
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (11) : 1465 - 1469
12345